SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Aiolos Bio, Inc. (“Aiolos” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on addressing the unmet treatment ...
WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in a Phase 2 clinical ...
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 23, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first data readout expected in mid-2026 WIN378 has the potential to be the ...
NEWARK, Del. and NANJING, China, June 11, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today presented key results from the ADAMANT study, a phase 2 proof-of-concept ...
BASEL, Switzerland, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological ...
The MarketWatch News Department was not involved in the creation of this content. -- Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a ...
Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results